You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Treatment for Alcohol-associated Liver Disease

    SBC: MITOTHERAPEUTIX, LLC            Topic: 350

    Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of preventable morbidity and mortality. In the U.S., alcohol abuse impacts over 10 million individuals ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 104

    Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers

    SBC: BORROW MY GLASSES LLC            Topic: NIA

    1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Genome Editing Therapy for Usher Syndrome Type 3

    SBC: GENETOBE INC            Topic: NEI

    PROJECT SUMMARY/ABSTRACTUsher syndrome type 3A (USH3A), an autosomal recessive disorder, is characterized by progressive loss of hearing and vision due to a clarin-1 (CLRN1) gene mutation. A person with type 3 Usher syndrome will usually require cochlea implants by mid- to late adulthood and classified as being legally blind. The management of the chronic, progressive, severe vision loss (retiniti ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Closed-loop laryngeal pacing for voice restoration

    SBC: RIPPLE LLC            Topic: NIDCD

    Project Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Self-Guided Mobile Intervention for Adults with Binge Eating and Obesity

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7 Health complications due to obesity comprise more than 20% of the nation’s healthcare budget, and the healthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13 The prevalence of binge eating and the substantial burden of healthc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Precision Medicine for Alcohol-Associated Liver Disease

    SBC: GENETOBE INC            Topic: 150

    ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Noregen, a regenerative medicine ocular therapeutic

    SBC: Retinal Solutions LLC            Topic: NEI

    ABSTRACT Ischemic retinopathies, such as diabetic retinopathy and retinal vein occlusion, are the leading cause of blindness in the United States. Common features are leaky vessels, swelling, capillary drop out, aberrant vessel growth and retinal detachment. Current treatments include laser ablation, anti-VEGFs and steroids. All are sub-optimal and only serve to slow disease progression and vision ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government